Small amounts of cell-free DNA circulate in both healthy and diseased human blood, while increased concentrations of DNA are present in the serum of cancer patients. Tumor-specific mutations or epigenetic modifications have predominantly been detected in tissue specimens. The purpose of this study was to investigate methylation of five different genes involved in tumor suppression and DNA repair (suppressors of cytokine signaling 1 and 2 (SOCS1, SOCS2)), Ras-association domain family protein 1A (RASSF1a), D-type p16
INTRODUCTION
The presence of circulating nucleic acids in serum and plasma has been described many years ago (Mandel and Métais, 1947; Tan et al., 1966; Koffler et al., 1973) . By using radioimmunoassays, it has been discovered that cancer patients have higher levels of circulating DNA than those with nonmalignant diseases and healthy controls (Leon et al., 1977) . With the development of more sensitive molecular techniques such as semiquantitative PCR, a renewed interest in circulating DNA has emerged. Many studies have focused on the detection of genetic changes in DNA isolated from tumor tissue. A major effort has been placed on the detection of mutations, loss of heterozygosity, microsatellites, and the methylation status of such DNA (Vasioukhin et al., 1994; Nawroz et al., 1996; Wong et al., 1999) . A considerable proportion of the circulating DNA is released during apoptotic cell death. The rate of apoptosis is dysregulated in many pathological conditions such as degenerative, traumatic, ischemic, inflammatory, and malignant diseases (Holdenrieder et al., 2005) . Several studies have demonstrated tumor-specific alterations in DNA recovered from plasma or serum of patients with various malignancies, a finding with great potential for molecular diagnosis and prognosis estimation (Fujiwara et al., 1999; Johnson and Lo, 2002; Sidransky, 2002; Usadel et al., 2002) . Recently, Widschwendter and Jones (2002) have described the potential of circulating DNA in the serum of women with breast cancer to predict the course of disease by analyzing DNA methylation of tumor suppressor genes (TSGs). Very recently, the potential of circulating DNA as a prognostic tool for squamous cell carcinoma (Hamana et al., 2005) and gastric cancer (Leung et al., 2005) has been reported.
In higher eukaryotes, DNA is methylated exclusively at cytosines located 5 0 to guanosine within cytosine-phosphoguanosine (CpG) dinucleotides. This modification has important regulatory effects on gene expression, especially when involving CpG-rich areas known as CpG islands, located in or near the promoter regions of many genes (Jones and Baylin, 2002; Laird, 2003) . While almost all geneassociated islands are protected from methylation on autosomal chromosomes, extensive methylation of CpG islands has been associated with transcriptional inactivation of selected imprinted genes and genes on the inactive X-chromosome of females (Singer-Sam et al., 1990) . Aberrant methylation of normally unmethylated CpG islands has been documented as a relatively frequent event in immortalized and transformed cells, and has been associated with transcriptional inactivation of defined TSG in human cancer (Dammann et al., 2000) . Notably, this alteration has been described to occur in a very early stage of carcinogenesis (Fujiwara et al., 2005) .
Our study evaluated the methylation status of five different TSGs/DNA repair genes (suppressors of cytokine signaling (SOCS)1, SOCS2, Ras-association domain family protein 1A (RASSF1a), cyclin-dependent kinase inhibitor (CDKN)2a, and O 6 -methylguanine DNA-methyltransferase (MGMT)) in the serum of 41 melanoma patients. Moreover, the messenger ribonucleic acid transcripts for these genes were also studied in melanoma lesions relative to normal skin. We provide evidence for epigenetic inactivation and reduced TSG expression in the serum and tissue of melanoma patients.
RESULTS

Patients
Patients' characteristics are depicted in Table 1A and B. Patients suffered from primary melanoma (n ¼ 28; mean age: 60.3 years, range 36-78 years) and metastases (n ¼ 13; mean age: 61.8 years, range 23-78 years). In all, 13 healthy individuals without nevi 45 mm (mean age: 54 years, range 37-71 years) and 10 patients with more than 15 benign nevi 45 mm (mean age: 39 years, range 21-65 years) were used as controls (Table 1C) . For comparison, sera from patients with other skin tumors (nine basal cell cancers, five Kaposi's sarcoma) as well as different metastasized cancers (five breast cancers, five colon cancers) and 12 patients with chronic inflammatory diseases (psoriasis and eczema) were also analyzed (Table 1C) .
Detection of cell-free DNA in plasma
The average DNA recovered from donor controls was 26.5 ng DNA/ml, and from melanoma patients 56 ng DNA/ml, respectively (Figure 1) . Likewise, patients with other metastatic cancers also had elevated levels (Figure 1 ). Patients with nonmetastasizing basal cell cancers had the lowest concentrations of cell-free DNA (Po0.05 compared to healthy controls) despite their high mean age of 77 years ( Figure 1 ). Individuals suffering from chronic inflammatory diseases also showed moderately elevated levels of circulating DNA compared with healthy individuals of different age (Figure 1 ).
Quantitative methylation analysis of selected genes
Initially, five candidate genes involved in tumor suppression, cell cycle, and DNA repair (SOCS1, SOCS2, RASSF1a, CDKN2a (p16
INK2a
), and MGMT) were selected for analysis of CpG promoter regions using methylation-specific PCR. The results indicated that the most frequently methylated genes in the serum were SOCS1 (75%), CDKN2a (75%), RASSF1a (64%), MGMT (64%), and SOCS2 (43%), respectively ( Table 2) . In more detail, a box plot analysis provides an excellent visual summary of the quantitative distribution of methylated promoter DNA (Figure 2 ). The box stretches from the lower hinge (defined as the 25th percentile) to the upper hinge (the 75th percentile) and therefore contains the middle half of the scores in the distribution. The median is shown as a line across the box. As can be seen in Figure 2 , primary melanoma and melanoma metastases generally demonstrated the highest levels of methylation ( Figure 2 ). Of the 41 melanoma patients, 83% had one hypermethylated gene, while 66, 51, and 41% had two, three, or four hypermethylated genes, respectively. In all, 20% of these patients showed hypermethylation for all genes and only 17% showed no methylation. In basal cell cancers 86% had methylated RASSF1a and 43% had methylated CDKN2a (p16
), while the other genes showed methylations in less than 30% (Table 2 and Figure 2 ). Serum from patients with other metastasized cancers showed methylation of individual genes in up to 20% (Table 2 ). Serum from 10 nevus patients as well as from healthy controls without nevi showed no significant methylation (Table 2 and Figure 2 ). Importantly, the methylation profile of the selected genes from melanoma patients was distinct from the other tumors analyzed. Interestingly, individuals suffering from chronic inflammatory diseases showed a high level (75%) of methylation for CDKN2A ( Table 2 ). The methylation analysis for the different age groups showed no significant differences either for patients or for healthy controls (Table 2 and data not shown).
Gene expression of target genes in primary tumors
The mRNA expression of SOCS1, SOCS2, CDKN2a (p16 Table 2 . Frequency of promoter methylation for the different analyzed genes in the melanoma group and different control groups (Table 3) . Interestingly, MGMT showed a significant upregulation (12.4 times, Po0.001) in comparison with normal human melanocyte cultures (Table 3) .
Pyrosequencing of SOCS2
To further analyze the positional methylation of the promoter region, we selected the SOCS2 gene that showed strongly reduced transcript levels in melanoma specimens and significant qualitative methylation. Two different CpG sites (#1 at position 2,249 and #2 at 2,258) were analyzed (Figures 3 and 4a) . As compared to the SOCS2 threshold of 0.2 in healthy individuals, all methylation events at position #2 from the DNA of patients with primary melanoma and metastases were considered significant (Figure 4b ).
DISCUSSION
Cancer is one of the most common reasons for death in the world. Early detection and close follow-up are crucial for The gene expression level of the studied TSG was normalized to three pooled NHM cultures. As depicted, the expressions of SOCS1, SOCS2, RASSF1a, and CDKN2a were significantly downregulated, while MGMT showed a significantly higher level. silencing of various genes in several types of cancer (Nagai et al., 2002 (Nagai et al., , 2003 Fukushima et al., 2003; Galm et al., 2003; He et al., 2003; Uehara et al., 2003; Yang et al., 2003; Li et al., 2004) . Profiling studies have revealed the frequency of gene hypermethylation and identified specific genes for different histological origins (Esteller et al., 2001; Widschwendter and Jones, 2002; Toyooka et al., 2003) . However, there are only very few studies which have focused on gene hypermethylation in primary tumors versus metastases (Hoon et al., 2004) . There is a clear indication that hypermethylation of the TSG promoter region is an essential mechanism by which gene transcription may be turned off in cancer cells. Of the five genes studied, we found that the most frequently methylated genes in the serum of melanoma patients were SOCS1 and CDKN2a (p16 ), followed by RASSF1a, MGMT, and SOCS2. The analysis for methylation in the different stage and age groups revealed no significant differences.
For instance, the SOCS proteins have an important role as attenuators of cytokine-mediated processes, suggesting a role in the suppression of tumorigenesis. Recently, SOCS-1 was found to be frequently silenced by hypermethylation in hepatocellular carcinoma (Yoshikawa et al., 2001) , SOCS-1, and SOCS-3 in squamous cell carcinoma of the head and neck (Weber et al., 2005) , pancreatic carcinoma (Fukushima et al., 2003) , and hepatoblastomas , and as newly reported by Sutherland et al. (2004) SOCS1 is also involved in breast cancer and primary ovarian cancer, while SOCS-2 is hypermethylated only in primary ovarian cancer.
Until today there are no studies looking at the expression and methylation of SOCS1 and SOCS2 in cutaneous melanoma in serum. Recently, Li et al. (2004) have shown the presence of SOCS1 in eight melanoma cell lines derived from different tumor stages and primary melanoma, respectively. Our data extend their finding showing significant methylation of SOCS1 in the sera of melanoma patients, leading to reduced SOCS1 gene transcription in vivo.
Understanding the physiological role of RASSF1a is still in its early stage (Agathanggelou et al., 2005) . As reported by Dammann et al. (2000) , hypermethylation of the RASSF1a gene promoter correlates with loss of gene expression in lung cancer. Further studies have shown that the aberrant methylation of this gene is involved in many types of carcinomas, including breast, prostate, ovarian, kidney, gastric bladder, and nasopharyngeal (Lo et al., 2001; Liu et al., 2002) . As shown by Spugnardi et al. (2003) , RASSF1a is inactivated due to hypermethylation of its CpG islands in melanoma cell lines and tumor biopsies. Since we also observed a significant downregulation of RASSF1a in melanoma tissue, we decided to look at the methylation of the promoter region of this gene in the sera of melanoma patients. Our data on RASSF1a methylation in serum confirmed the finding of Spugnardi et al. (2003) obtained from tumor tissue and cell lines.
The p16 INK4a gene encodes a protein, P16, which is a D-type cyclin-dependent kinase inhibitor that blocks the ability of CDK4 to interact with cyclin D and stimulate the progression of eukaryotic cells through the G1 phase of the cell cycle (Serrano et al., 1993) . To date, CDKN2a (p16 INK2a ) has been the most studied gene for aberrant promoter methylation in melanoma (Fujimoto et al., 1999; Merbs and Sidransky, 1999) . By studying the methylation status of this gene in patient serum, we have shown that there is a high frequency of methylation in melanoma and basal cell cancer patients. This result correlates well with decreased mRNA Table 4 . Hybridization probes and primers were designed using Primer Express s version 2.0 (Perkin-Elmer Applied Biosystems Inc., Warrington, UK), based on sequences from the GenBank database (top: primer sequences used for real-time PCR with SYBR s assay; bottom: primer sequences used for MSP) transcription of this gene in the tumors. Interestingly, individuals with basal cell cancer showed methylation for CDKN2A in 43% and RASSF1a in 86%. As epigenetic mosaicism has potential implications for the pathogenesis of several age-related diseases, the validity of our results in this patient population was confirmed by the absence of similar methylation events in an age-related control group. However, older individuals with inflammatory diseases also showed increased levels of methylation, which has recently been reported (Holdenrieder et al., 2005) . MGMT, a DNA repair gene, serves as a key regulator of genome integrity. Studies have shown that MGMT expression protects mammalian cell lines from spontaneous G:C to A:T transitions (Christmann et al., 2001) . Lately, Hoon et al. (2004) showed methylation of MGMT in 34% of metastatic tumor specimens and also in the plasma of melanoma patients. However, contradicting reports exist as to the presence of MGMT methylation in melanoma. For instance, Paz et al. (2003) or Furuta et al. (2004) analyzed the MGMT methylation of the enhancer and the minimal promoter region by methylation-specific PCR and found no methylation. Nakagawachi et al. (2003) recently pointed to the importance of the position for MGMT silencing.
Our data on pyrosequencing for the SOCS2 promoter serve as an example to identify the critical CpG sites whose methylation results in decreased gene expression. Additional detailed pyrosequencing studies are necessary to identify the critical CpG island for all genes to be analyzed. These positional methylation experiments will undoubtedly help to resolve some of the controversies in semiquantitative studies published up to now.
Circulating methylated DNA and detection of TSG promoter methylation in serum may hold promise as a surrogate marker of cancer to detect recurrence or progression. Detailed studies on larger numbers of patients are needed to reveal their potential usefulness as a surrogate marker.
MATERIALS AND METHODS
Patients and serum samples
A total of 100 peripheral blood specimens were collected. We analyzed the sera from 41 patients (stage I ¼ 18; stage II ¼ 10; stage III/IV ¼ 13). For comparison, sera from 13 healthy controls without nevi and 10 individuals with more than 15 nevi of 45 mm in size and patients with other skin tumors (nine basal cell cancers, five Kaposi's sarcoma) as well as different cancers (five breast cancers, five colon cancers) were used as controls. In addition, we examined 12 individuals suffering from chronic inflammatory diseases such as psoriasis and eczema.
The experiments received institutional approval and patients consented to the blood analysis. The protocol adhered to the Declaration of Helsinki Principles.
Sample preparation
Genomic DNA was isolated from 1 ml serum using QIAmp Ultrasense blood mini kit (Qiagen) according to the manufacturer's protocol, with an elution volume of 50 ml. DNA samples were frozen at À701C until further processing.
Analysis of DNA methylation
Chemical modification of unmethylated, but not of the methylated, cytosines to thymidine within CpG islands using sodium bisulfite treatment was performed using the CpG TM DNA modification kit (Chemicon). The protocol was modified by using 3 mg of serum DNA. After bisulfite modification, the DNA was eluted in 75 ml H 2 O. Primers and probes were designed to specially amplify the bisulfiteconverted promoter of the genes of interest. Primers and probes of the b-actin gene were located in an area lacking CpG nucleotides; thus, the amplification of the reference gene by methylation-specific PCR occurred independently of the CpG island methylation status, whereas the amplification of the TSG was proportional to the degree of cytosine methylation within the promoter. The methylation status was defined as the ratio of the fluorescence emission intensity values for each gene's PCR product to those of the b-actin PCR products obtained by the SYBR analysis (see below) (Widschwendter et al., 2004; Lehmann et al., 2005) . A threshold was defined individually for every gene: the ratio (target gene:b-actin) was used as a relative measure for the level of the methylated target gene DNA in a particular sample. The PCR was performed in triplicates for each primer/probe set. Analysis of methylation of the b-actin gene was run in all samples for verification of modified DNA. A gene was deemed as methylated if this value was 41.
Quantitative real-time PCR and isolation of total RNA Total RNA from fresh tumors was isolated using Trizol s according to the manufacturer's recommendation (Invitrogen Life Technology). First-strand cDNA was synthesized in 20 ml reaction volume containing 5 mM MgCl 2 , 1 mM dNTP mix, 1 Â PCR buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.3), 2.5 mM random hexamer, 1 U/ml RNA guard, 2.5 U/ml MuLV reverse transcriptase, and 1 mg of total RNA. Samples were incubated for 10 minutes at 201C, and for 15 minutes at 421C, followed by 5 minutes at 991C. The quality of the resulting cDNA was checked by electrophoresis on a 3% (w/v) agarose gel. The cDNA was diluted four times before using in PCR. Statistical analysis was performed using the Student's t-test.
Quantitative PCR based on the use of fluorogenic probes and SYBR s green
The SYBR s green assay was used for all five genes listed above (Giglio et al., 2003) . Additionally, we confirmed the results for three genes (SOCS1, RASSF1a, CDKN2a) using the TaqMan s technique. Transcript analysis of fresh tumors was performed by real-time PCR using the SYBR s assay. Hybridization probes and primers were designed using Primer Express s version 2.0 (PerkinElmer Applied Biosystems Inc., Warrington, UK), based on sequences from the GenBank database (Table 4) . Typically, PCR was carried out in a 96-well plate containing 25 ml volumes, including universal master mix (1 Â ), 600 nM forward primers, and 600 nM reverse primer. A fluorescent dye, 6-carboxyl-X-rhodamin, was included in the TaqMan s buffer to serve as an internal reference. Thermal cycling was initiated with a first denaturation step for 10 minutes at 951C, followed by 50 cycles performed in two steps: for 15 seconds at 951C and for 1 minutes at 601C. When using the SYBR s assay, a dissociation curve was plotted after 50 PCR cycles and analyzed to confirm the specificity of the PCR products (Giglio et al., 2003) . All samples were amplified simultaneously in triplicates in a one-assay run. Variation coefficients for C T values for www.jidonline.org 429 A Marini et al.
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Pyrosequencing
The Gene2Promoter software (www.genomatix.de; Genomatix Software, Munich, Germany) allows the automated extraction of groups of promoters from a list of accession numbers or gene IDs. We extracted 2,500 bp upstream and 500 bp downstream around the transcription start site of the promoter region. Subsequently, CpG islands were identified within this core promoter region using the EMBL EBI-CpG plot (www.ebi.ac.uk/emboss/cpgplot/index. html).
For primer design, the DNA sequences were converted in silico to the methylated form of CpG as follows: find CG, convert to YG, and subsequently find C, convert to T, with Y equaling either C/T or G/A. Using this converted sequence, methylation-specific primers for pyrosequencing of SOCS2 CpGs were designed using the Biotage Assay Design soft ware (Biotage, Uppsala, Sweden).
F-primer,
Biotin-TTAAAGAGGGTAAGTGTT TTGTGT R-primer, TAGATTTTAAGGTTGGGAGTTGG reverse complementary Sequencing Primer, AATAAAGTTTTTTGTTAGTT reverse complementary, AACTAACAAAAAACTTTATT.
PCR conditions for pyrosequencing
Bisulfite-treated DNA (50 ng) from serum was used in the PCR reaction with 10 mM forward and reverse primers, respectively. PCR conditions for SOCS2 were 1 Â 951C for 15 minutes (951C 40 s; 551C 40 seconds; 721C 40 seconds), 50 cycles, 1 Â 721C 10 min. For statistical analysis, the coefficient of variation was calculated for SOCS2 methylation of healthy individuals versus patients with nevi, melanoma, and melanoma metastases, respectively. A coefficient of variation greater than the threshold of 0.2 was considered significant.
